Is there a way to treat liver metastasis secondary to uveal melanoma without introducing systemic, treatment-related toxicity? Dr. Altan Ahmed (interventional radiologist at Moffitt Cancer Center) and Dr. Sid Padia (interventional radiologist at UCLA) join guest-host Dr. Kavi Krishnasamy to discuss HEPZATO, a novel device-based treatment for liver metastases from uveal melanoma.

---

This podcast is supported by:

RADPAD® Radiation Protection

https://www.radpad.com/

---

SYNPOSIS

Dr. Ahmed and Dr. Padia begin by exploring the design and setup of the HEPZATO clinical trials, while also speaking on patient selection criteria. The doctors then talk through the technical aspects of the intervention. After covering workflow and considerations related to procedure timing and coordination, the doctors go on to discuss drug dosing and optimizing treatment cycles. The episode concludes with current gaps in literature, current and future research aims, and potential future applications of the HEPZATO modality in treating other malignancies such as colorectal cancer.

---

TIMESTAMPS

00:00 - Introduction

05:40 - Patient Selection Criteria

09:49 - Workflow

19:17 - Procedure Timing and Coordination

29:39 - Challenges and Considerations in Drug Dosing

32:39 - Optimizing Treatment Cycles and Patient Response

37:56 - Managing Post-Treatment and Adverse Effects

43:43 - Future Research and Gaps in Current Interventions

50:45 - Exploring New Applications for PHP Therapy

55:02 - Conclusion

---

RESOURCES

Hepzato:

https://hepzatokit.com/

FOCUS Trial - Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study:

https://pubmed.ncbi.nlm.nih.gov/38704501/

FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A):

https://ascopubs.org/doi/pdf/10.1200/JCO.2022.40.16_suppl.9510

Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial:

https://pubmed.ncbi.nlm.nih.gov/36624292/

Troponin Elevation in Patients Undergoing Percutaneous Hepatic Perfusion for Metastatic Uveal Melanoma:

https://pmc.ncbi.nlm.nih.gov/articles/PMC11010739/

Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study:

https://pmc.ncbi.nlm.nih.gov/articles/PMC7801354/

Southampton group - Quality of life after melphalan percutaneous hepatic perfusion for patients with metastatic uveal melanoma:

https://pmc.ncbi.nlm.nih.gov/articles/PMC10906212/

Leiden group - Quality of Life Analysis of Patients Treated with Percutaneous Hepatic Perfusion for Uveal Melanoma Liver Metastases:

https://pubmed.ncbi.nlm.nih.gov/38587534/